Vasopressin and methylprednisolone improve outcomes during in hospital cardiac arrest: JAMA

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-10-01 02:15 GMT   |   Update On 2021-10-01 02:20 GMT
Advertisement

Vasopressin and methylprednisolone improve the return of spontaneous circulation in Patients with In-Hospital cardiac arrest, suggests a study published in the JAMA.

Previous trials have suggested that vasopressin and methylprednisolone administered during in-hospital cardiac arrest might improve outcomes.

A group of researchers from Denmark conducted a study to determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves the return of spontaneous circulation.

Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark. A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021. The last 90-day follow-up was on April 21, 2021.

Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or a placebo (n = 267). The first dose of vasopressin (20 IU) and methylprednisolone (40 mg), or corresponding placebo, was administered after the first dose of epinephrine. Additional doses of vasopressin or corresponding placebo were administered after each additional dose of epinephrine for a maximum of 4 doses.

The results of the study are as follows:

· Among 512 patients who were randomized, 501 met all inclusion and no exclusion criteria and were included in the.

· One hundred of 237 patients (42%) in the vasopressin and methylprednisolone group and 86 of 264 patients (33%) in the placebo group achieved return of spontaneous circulation.

· At 30 days, 23 patients (9.7%) in the intervention group and 31 patients (12%) in the placebo group were alive.

· A favourable neurologic outcome was observed in 18 patients (7.6%) in the intervention group and 20 patients (7.6%) in the placebo group at 30 days (risk ratio, 1.00; risk difference, 0.0%.

· In patients with return of spontaneous circulation, hyperglycemia occurred in 77 (77%) in the intervention group and 63 (73%) in the placebo group.

· Hypernatremia occurred in 28 (28%) and 27 (31%), in the intervention and placebo groups, respectively.

Thus, the researchers concluded that among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation. However, there is uncertainty whether this treatment results in benefit or harm for long-term survival.

Reference:

Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients with In-Hospital Cardiac Arrest: A Randomized Clinical Trial by Andersen L et. al published in the JAMA.

doi:10.1001/jama.2021.16628



Tags:    
Article Source : JAMA

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News